The global antiviral drugs market is poised for consistent growth, projected to expand at a compound annual growth rate (CAGR) of 3.9% from 2023 to 2033. Starting at an estimated value of USD 61.42 billion in 2023, the market is anticipated to reach USD 89.68 billion by the end of the forecast period.
This growth is driven by the increasing prevalence of viral infections, advancements in antiviral drug development, and rising investments in healthcare infrastructure. The global demand for effective treatments for conditions like HIV, hepatitis, and influenza is a key contributor to market expansion.
Innovations in antiviral therapies, including combination treatments and long-acting formulations, are also enhancing patient outcomes and fueling market demand. Furthermore, heightened awareness and proactive measures for pandemic preparedness are expected to sustain interest in antiviral drug development.
A Comprehensive Full Report – https://www.futuremarketinsights.com/reports/anti-viral-drugs-market
Key Takeaways:
- The antiviral drugs market is projected to grow at a 3.9% CAGR, reaching USD 89.68 billion by 2033 from USD 61.42 billion in 2023.
- Rising cases of viral infections and ongoing advancements in drug development drive market growth.
- Demand for improved treatments for HIV, hepatitis, and influenza remains a significant growth factor.
- Innovations in combination therapies and pandemic preparedness initiatives enhance market potential.
Market Drivers
- Prevalence of Viral Infections: The increasing incidence of viral diseases, including HIV, influenza, and hepatitis, is driving demand for effective antiviral treatments.
- Advancements in Drug Development: Continuous research and development efforts are leading to the introduction of new antiviral drugs that are more effective against resistant strains of viruses.
- Government Initiatives: Increased government funding and initiatives aimed at combating viral infections are supporting market growth.
- Rising Awareness: Growing public awareness about the importance of antiviral treatments in managing viral infections is contributing to market expansion.
- Aging Population: The rise in the elderly population, who are more susceptible to viral infections, is further driving the demand for antiviral drugs.
Competitive Landscape
Recent Developments:
- In May 2022, Cipla Limited, in partnership with Genes2Me Pvt. Ltd., announced the commercialization of the ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India. Cipla is increasing its diagnostics portfolio in an attempt to take more innovative and innovative solutions to the market.
- In May 2022, Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company’s manufacturing plant in Michigan to help ease a nationwide shortage of baby formula after the facility was closed due to bacterial contamination.
- In March 2022, Scripps Research, non-profit research and technology drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel, immediate antiviral treatments for COVID-19.
- The European Commission has approved Roche’s Xofluza for the advanced treatment of influenza. The commission has approved the single dose for patients.
- Gilead has introduced Veklury for pediatric patients that are hospitalized and not hospitalized.
Key Players
- Roche
- Gilead
- GlaxoSmithKline
- Bristol-Myers-Squibb
- Abbott
- AstraZeneca
- Cipla
- Bayer AG
- Johnson & Johnson
- Merck & Co
- AbbVie
- Aurobindo Pharma
- Dr. Reddy’s Laboratories Ltd.
Key Segments Covered
By Product type:
- Hepatitis-C antivirals
- HIV antivirals
- Herpes antivirals
- Hepatitis-B antivirals
- Influenza antivirals
- Others (Pneumonia, Flu, etc.)
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Key Regions Covered:
- North America
- United States
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Germany
- United Kingdom
- France
- Spain
- Russia
- Rest of Europe
- Japan
- Asia Pacific Excluding Japan
- China
- India
- Malaysia
- Singapore
- Australia
- Rest of Asia Pacific Excluding Japan (APEJ)
- The Middle East and Africa
- GCC Countries
- Israel
- South Africa
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
